Am­gen tops cost watch­dog's price gougers list based on 'un­sup­port­ed' in­creas­es for En­brel with­out mean­ing­ful da­ta

In a top 10 rank­ing of the most egre­gious price gougers from 2019, Am­gen’s En­brel topped US cost watch­dog ICER’s naughty list with “un­sup­port­ed” markups that added as much as $403 mil­lion to the na­tion’s drug spend dur­ing that time.

Price in­creas­es for some of phar­ma’s most pop­u­lar drugs have long been a fo­cus of con­sumer ire, but the in­dus­try has ar­gued those in­creas­es are rou­tine and meant to cov­er the cost of R&D in­no­va­tion. With­out mean­ing­ful guid­ance at the state or fed­er­al lev­el, ICER looked to con­nect how much a drug had pro­gressed in the clin­ic com­pared with its in­crease in both whole­sale and net price in 2019.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.